 | Up a level |
Journal Article
Althoff, K., Leitzke, S., Herling, C., Frenzel, L., Schiller, J., Herling, M., Holtick, U., Scheid, C. and Theurich, S. (2018). Metabolic status and immune activation prior conditioning influence clinical outcomes in patients after allogeneic hematopoietic stem cell transplantation. Oncol. Res. Treat., 41. S. 66 - 67. BASEL: KARGER. ISSN 2296-5262
Balavarca, Y., Pearce, K., Norden, J., Collin, M., Jackson, G., Holler, E., Dressel, R., Kolb, H-J, Greinix, H., Socie, G., Toubert, A., Rocha, V., Gluckman, E., Hromadnikova, I., Sedlacek, P., Wolff, D., Holtick, U., Dickinson, A. and Bickeboeller, H. (2015). Predicting survival using clinical risk scores and non-HLA immunogenetics. Bone Marrow Transplant., 50 (11). S. 1445 - 1453. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Borchmann, P., Juehling, A., Goedel, P., Balke-Want, H., Schmid, C., Ayuk, F., Holtkamp, S., Preussner, L., Zadoyan, G., Hanssens, L., Kaiser, A., Jurk, M., Buerger, I, Schneider, D., Dropulic, B., Overstijns, T., Holtick, U., Scheid, C., Miltenyi, S. and Hallek, M. (2020). Phase I trial of MB-CART2019.1, a novel CD20 and CD19 targeting tandem chimeric antigen receptor, in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma. Oncol. Res. Treat., 43 (SUPPL 4). S. 56 - 57. BASEL: KARGER. ISSN 2296-5262
Chakupurakal, G., Garcia-Marquez, M., Shimabukuro vorn-hagen, A., Schloesser, H., Holtick, U., Scheid, C. and von Bergwelt-Baildon, M. (2015). Changes in T and B- cells in steroid refractory GvHD patients following treatment with a CD25-antibody. Bone Marrow Transplant., 50. S. S177 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Chakupurakal, G., Garcia-Marquez, M., Shimabukuro vorn-hagen, A., Schloesser, H., Holtick, U., Scheid, C. and von Bergwelt-Baildon, M. (2015). Changes in T and B- cells in steroid refractory GvHD patients following treatment with a CD25-antibody. Bone Marrow Transplant., 50. S. S177 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Chakupurakal, G., Garcia-Marquez, M., Shimabukuro-Vorn-hagen, A., Theurichi, S., Scheid, C., Hallek, M., Holtick, U. and von Bergwelt-Baildon, M. (2015). IL-10 producing B-10 cells can be identified as early as 30 days post an allogeneic stem cell transplant and are enriched in the transitional B-cell compartment. Bone Marrow Transplant., 50. S. S176 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Chakupurakal, G., Garcia-Marquez, M., Shimabukuro-Vorn-hagen, A., Theurichi, S., Scheid, C., Hallek, M., Holtick, U. and von Bergwelt-Baildon, M. (2015). IL-10 producing B-10 cells can be identified as early as 30 days post an allogeneic stem cell transplant and are enriched in the transitional B-cell compartment. Bone Marrow Transplant., 50. S. S176 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Chakupurakal, G., Leitzke, S., Langerbeins, P., Schiller, J., Schneider, P. M., Holtick, U., Shimabukuro-Vornhagen, A., Theurich, S., Chemnitz, J., Hallek, M., von Bergwelt-Baildon, M. and Scheid, C. (2015). Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality-a single institution experience. Ann. Hematol., 94 (10). S. 1717 - 1726. NEW YORK: SPRINGER. ISSN 1432-0584
Engel, L. A., Wittig, S., Bock, F., Sauerbier, L., Scheid, C., Holtick, U., Chemnitz, J-M, Hallek, M., Cursiefen, C. and Steven, P. (2015). Meibography and meibomian gland measurements in ocular graft-versus-host disease. Bone Marrow Transplant., 50 (7). S. 961 - 968. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Farowski, F., Bueker, V., Vehreschild, J. J., Biehl, L., Cruz-Aguilar, R., Scheid, C., Holtick, U., Jazmati, N., Wisplinghoff, H., Cornely, O. A. and Vehreschild, M. J. G. T. (2018). Impact of choice, timing, sequence and combination of broad-spectrum antibiotics on the outcome of allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant., 53 (1). S. 52 - 58. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Holtick, U., Frenzel, L., Froehlich, H., Shimabukuro-Vornhagen, A., Theurich, S., Claasen, J., Scheid, C., von Bergwelt-Baildon, M., Wendtner, C. and Chemnitz, J. (2014). INCREASED FUNCTIONAL T CELL DEFECTS IN PATIENTS WITH LOW CD4 COUNTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION. Bone Marrow Transplant., 49. S. S558 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Holtick, U., Herling, M., Pflug, N., Chakupurakal, G., Leitzke, S., Wolf, D., Hallek, M., Scheid, C. and Chemnitz, J. (2016). Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol containing treosulfan in an elderly population with AML. Bone Marrow Transplant., 51. S. S442 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Holtick, U., Herling, M., Theurich, S., Frenzel, L., Herling, C., Schiller, J., Hallek, M. and Scheid, C. (2018). A phase II study to investigate the efficacy of short-term everolimus in addition to post-transplant cyclophosphamide as graft-versus-host-prophylaxis after allogeneic hematopoietic stem cell transplantation (OCTET-EVER). Oncol. Res. Treat., 41. S. 63 - 64. BASEL: KARGER. ISSN 2296-5262
Holtick, U., Shimabukuro-Vornhagen, A., Chakupurakal, G., Theurich, S., Leitzke, S., Wolf, D., Hallek, M., von Bergwelt-Baildon, M., Scheid, C. and Chemnitz, J. (2015). FLAMSA reduced-intensity regimen in high-risk AML patients - role of re-induction and disease state prior to transplant. Bone Marrow Transplant., 50. S. S443 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Holtick, U., Shimabukuro-Vornhagen, A., Chakupurakal, G., Theurich, S., Leitzke, S., Wolf, D., Hallek, M., von Bergwelt-Baildon, M., Scheid, C. and Chemnitz, J. (2015). FLAMSA reduced-intensity regimen in high-risk AML patients - role of re-induction and disease state prior to transplant. Bone Marrow Transplant., 50. S. S443 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Pearce, K. F., Balavarca, Y., Norden, J., Jackson, G., Holler, E., Dressel, R., Greinix, H., Toubert, A., Gluckman, E., Hromadnikova, I., Sedlacek, P., Wolff, D., Holtick, U., Bickeboeller, H. and Dickinson, A. M. (2016). Impact of genomic risk factors on survival after haematopoietic stem cell transplantation for patients with acute leukaemia. Int. J. Immunogenet., 43 (6). S. 404 - 413. HOBOKEN: WILEY. ISSN 1744-313X
Pflug, N., Chakupurakal, G., Theurich, S., Holtick, U., Leitzke, S., Chemnitz, J., Scheid, C., Hallek, M. and von Bergwelt-Baildon, M. (2018). Addition of rituximab to nonmyeloablative allogeneic transplantation for CLL and Richter's transformation - a single center experience. Oncol. Res. Treat., 41. S. 102 - 103. BASEL: KARGER. ISSN 2296-5262
Piechotta, V, John, L., Jung, J., Graziani, G., Reinhardt, H., Holtick, U., Semrau, R., Trog, D., Voelker, L. A., Herling, M., Fend, F., Harder, L., Weinhold, N., Kriegsmann, K., Merz, M., Delorme, S., Derlin, T., Raab, M. S., Goede, V, Schubert, M., Hohloch, K., Senf, B., Simon, S. T., Baumann, W., Fetscher, S., Schinke, M., Holtkamp, U., Einsele, H., Engelhardt, M., Goldschmidt, H., Scheid, C. and Skoetz, N. (2020). Interdisciplinary guideline on diagnosis, therapy, and follow-up of adult patients with monoclonal gammopathy of undetermined significance or multiple myeloma. Oncol. Res. Treat., 43 (SUPPL 4). S. 96 - 97. BASEL: KARGER. ISSN 2296-5262
Posdzich, P., Herling, M., Chemnitz, J., Leitzke, S., Di Christanziano, V, Hoeller, K., Kaiser, R., Scheid, C. and Holtick, U. (2016). BKV disease during the first 100 days after allogeneic hematopoietic stem cell transplantation - results of a screening program and retrospective analysis. Oncol. Res. Treat., 39. S. 80 - 81. BASEL: KARGER. ISSN 2296-5262
Richardson, T., Herling, M., Cruz-Aguilar, M. R., Frenzel, L. P., Hallek, M., Scheid, C. and Holtick, U. (2020). High-dose melphalan and autologous stem cell transplantation in elderly patients >= 70 years is safe and effective - A retrospective analysis. Oncol. Res. Treat., 43 (SUPPL 4). S. 107 - 108. BASEL: KARGER. ISSN 2296-5262
Scheid, C., Blommer, J., Holtick, U., Chemnitz, J., Malchau, G., Streichert, T. and Hallek, M. (2015). Using IgM hevylite to distinguish MGUS from malignant disorders with clonal IgM Paraprotein. Oncol. Res. Treat., 38. S. 239 - 240. BASEL: KARGER. ISSN 2296-5262
Scheid, C., Chemnitz, J., Herling, M., Pflug, N., Theurich, S., Burst, A., Leitzke, S., von Bergwelt-Baildon, M., Hallek, M. and Holtick, U. (2016). A ROLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN THE ERA OF NOVEL AGENTS FOR HODGKIN'S LYMPHOMA? Haematologica, 101. S. 55 - 57. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Scheid, C., Holtick, U., Bornhaeuser, M., Kroeger, N., Ganser, A., Arnold, R., Dreger, P., Stuhler, G., Theobald, M., Peschel, C., Hallek, M., Niederwieser, D., Finke, J., Hertenstein, B. and Beelen, D. (2015). Effects of Busulfan dose and administration route on transplantation outcome in adult patients with AML or MDS - a retrospective analysis of the German transplant registry DRST. Bone Marrow Transplant., 50. S. S224 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Scheid, C., Holtick, U., Bornhaeuser, M., Kroeger, N., Ganser, A., Arnold, R., Dreger, P., Stuhler, G., Theobald, M., Peschel, C., Hallek, M., Niederwieser, D., Finke, J., Hertenstein, B. and Beelen, D. (2015). Effects of Busulfan dose and administration route on transplantation outcome in adult patients with AML or MDS - a retrospective analysis of the German transplant registry DRST. Bone Marrow Transplant., 50. S. S224 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Sockel, K., Frank, S., Neu, A., Ditschkowski, M., Hilgendorf, I., Goeckenjan, M., Stoelzel, F., Middeke, J. M., Kroeger, N., Ayuketang, Ayuk F., Eder, M., Bethge, W., Finke, J., Bertz, H., Kobbe, G., Kaufmann, M., Platzbecker, U., Beverungen, D., Schmid, C., von Bonin, M., Heberling, L., Teipel, R., Bug, G., Fraccaroli, A., Tischer, J., Holler, B., Wolff, D., Luft, T., Roesler, W., Schaefer-Eckart, K., Dressler, S., Scheid, C., Holtick, U., Klein, S., Blau, I. -W., Burchert, A., Wulf, G., Hasenkamp, J., Kaun, S., Wittke, C., Wortmann, F., Bornhaeuser, M. and Schetelig, J. (2020). Evaluation of pregnancies after allogeneic stem cell transplantation during the last 15years in Germany. Oncol. Res. Treat., 43 (SUPPL 4). S. 240 - 241. BASEL: KARGER. ISSN 2296-5262
Steven, P., Faust, C., Holtick, U., Scheid, C., Tahmaz, V., Stern, M. E. and Gehlsen, U. (2020). Adverse environmental conditions are a risk factor for ocular GvHD after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant., 55 (9). S. 1851 - 1854. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Theurich, S., Iltgen, J., Wennhold, K., Marquez, M. Garcia, Rothschild, S., Schneider, B., Holtick, U., Thelen, M., Scheid, C., Becker, Hj, Schloesser, H., Reuter, S., Vornhagen, A. Shimabukuro and von Bergwelt-Baildon, M. (2016). THE JAK1/2 INHIBITOR RUXOLITINIB MODULATES ANTIGEN PRESENTING FUNCTIONS OF ACTIVATED PRIMARY B CELLS ON A METABOLIC LEVEL. Haematologica, 101. S. 462 - 463. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Theurich, S., Schlaak, M., Steguweit, H., Heukamp, L. C., Wennhold, K., Kurschat, P., Rabenhorst, A., Hartmann, K., Shimabukuro-Vornhagen, A., Schloesser, H., Holtick, U., Hallek, M., Stadler, R. and von Bergwelt-Baildon, M. (2014). Tumor infiltrating B-cells in primary cutaneous T-cell lymphoma correlate with disease progression and might represent a novel target for immunotherapy. Exp. Dermatol., 23 (3). S. E25 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1600-0625
Theurich, S., Schlaak, M., Steguweit, H., Heukamp, L. C., Wennhold, K., Kurschat, P., Shimabukuro-Vornhagen, A., Schloesser, H., Holtick, U., Hallek, M., Stadler, R. and von Bergwelt-Baildon, M. (2014). Tumor infiltrating B-cells in primary cutaneous T-cell lymphoma correlate with disease progression and might represent a novel target for immunotherapy. Oncol. Res. Treat., 37. S. 31 - 32. BASEL: KARGER. ISSN 2296-5262
Weihrauch, M. R., von Bergwelt-Baildon, M. S., Hacker, U., Richly, H., Holtick, U., Tschaika, M., Schmidt, M., Wittig, B., Nokay, B. and Scheulen, M. E. (2010). Immunotherapy with the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumors - clinical efficacy and immunological results of a phase I study. EJC Suppl., 8 (7). S. 23 - 25. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. ISSN 1359-6349
Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Ajib, S., de Fontbrune, Sicre F., Na, I. -K, Penter, L., Holtick, U., Wolf, D., Schuler, E., Meyer, E., Apostolova, P., Bertz, H., Marks, R., Luebbert, M., Waesch, R., Scheid, C., Ordemann, R., Bug, G., Kobbe, G., Negrin, R., Brune, M., Spyridonidis, A., Schmitt-Graeff, A., van der Velden, W., Huls, G., Grigoleit, G. U., Kuball, J., Blazar, B. R., Arnold, R., Kroeger, N., Passweg, J., Halter, J., Socie, G., Beelen, D., Peschel, C., Neubauer, A., Finke, J., Duyster, J. and von Bubnoff, N. (2015). Ruxolitinib for corticosteroid-refractory graft-versus-host disease: analysis of 95 patients treated at multiple medical centers. Oncol. Res. Treat., 38. S. 43 - 45. BASEL: KARGER. ISSN 2296-5262
Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S. K., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Ajib, S., de Fontbrune, F. S., Na, I-K, Penter, L., Holtick, U., Wolf, D., Schuler, E., Meyer, E., Apostolova, P., Bertz, H., Marks, R., Luebbert, M., Waesch, R., Scheid, C., Stoelzel, F., Ordemann, R., Bug, G., Kobbe, G., Negrin, R., Brune, M., Spyridonidis, A., Schmitt-Graeff, A., van der Velden, W., Huls, G., Mielke, S., Grigoleit, G. U., Kuball, J., Flynn, R., Ihorst, G., Du, J., Blazar, B. R., Arnold, R., Kroeger, N., Passweg, J., Halter, J., Socie, G., Beelen, D., Peschel, C., Neubauer, A., Finke, J., Duyster, J. and von Bubnoff, N. (2015). Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia, 29 (10). S. 2062 - 2069. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Zeiser, R., Lengerke, C., Spoerl, S., Maas-Bauer, K., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Sicre-de-Fontbrune, F., Na, I-K, Ajib, S., Verbeek, M., Nogai, H., Holtick, U., Wolf, D., Schuler, E., Meyer, E., Apostolova, P., Illert, L., Bertz, H., Marks, R., Waesch, R., Hackanson, B., Scheid, C., Ordemann, R., Bug, G., Kobbe, G., Negrin, R., Arnold, R., Kroeger, N., Passweg, J., Halter, J., Socie, G., Beelen, D., Finke, J., Peschel, C., Duyster, J. and von Bubnoff, N. (2015). High response rates in patients treated with ruxolitinib for corticosteroid-refractory Graft-versus-host disease: analysis including 13 Transplant Centers. Bone Marrow Transplant., 50. S. S22 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Zeiser, R., Lengerke, C., Spoerl, S., Maas-Bauer, K., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Sicre-de-Fontbrune, F., Na, I-K, Ajib, S., Verbeek, M., Nogai, H., Holtick, U., Wolf, D., Schuler, E., Meyer, E., Apostolova, P., Illert, L., Bertz, H., Marks, R., Waesch, R., Hackanson, B., Scheid, C., Ordemann, R., Bug, G., Kobbe, G., Negrin, R., Arnold, R., Kroeger, N., Passweg, J., Halter, J., Socie, G., Beelen, D., Finke, J., Peschel, C., Duyster, J. and von Bubnoff, N. (2015). High response rates in patients treated with ruxolitinib for corticosteroid-refractory Graft-versus-host disease: analysis including 13 Transplant Centers. Bone Marrow Transplant., 50. S. S22 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
von Bergwelt-Baildon, M., Holtick, U., Hallek, M. J. and Scheid, C. (2014). Hematopoietic stem cell transplantation. Bone marrow and blood stem cells. Internist, 55 (11). S. 1306 - 1313. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289